Monika Green

Head of Healthcare Consulting

"The challenges being faced by pharmaceuticmcal and biotech companies right now are immense. Drug pipelines are drying up, blockbusters are coming off patent, yet spending is spiralling. All the while, investors who have been spoilt by double digit growth in the industry for the last twenty years are putting the thumb screws on companies to maintain these returns.

Meanwhile, the baby biotech boom of the late 90s has stalled, the hype and euphoria surrounding the promises of the new technologies like genomics and gene therapy has shrivelled into a perceptive gloom as companies have failed to deliver, both technically and commercially.

To develop the drugs of tomorrow companies need to exploit their scientific technologies, their human talent and adopt competitive and innovative commercial strategies to succeed."

To request an interview, just click on the 'get in touch' button on the left

Experts Comments: